摘要
目的探讨单药或联合应用米拉贝隆和托特罗定缓释片治疗膀胱过度活动症(Overactive Bladder,OAB)的疗效及不良事件。方法筛选从2019年1月至2020年1月本院诊断OAB患者150例,分成A、B和C组,分别按1:1:1的比例分组。A组单用米拉贝隆,50mg/d。B组单用托特罗定缓释片,4mg/d。C组同时服用米拉贝隆和托特罗定缓释片,剂量同A、B组。治疗12周以后,根据基线水平到治疗结束时24小时尿失禁次数和排尿次数的变化情况评估其疗效,并对治疗期间的不良事件进行统计分析,评估其安全性。结果共获得143例(95.3%)可靠随访数据,平均年龄是49岁(19~78),109例(72.7%)OAB患者为女性。50例(33.3%)的患者出现≥1次不良事件。3组治疗组未发生严重不良事件,口干是最常见的不良事件(米拉贝隆,6%;托特罗定缓释片,12%;联合治疗组10%)。3组患者治疗后较前均显著改善(P<0.05),相比单药治疗,联合治疗组在尿失禁发生次数和排尿次数显著改善,具有统计学意义(P<0.05)。结论米拉贝隆联合托特罗定缓释片治疗OAB的有效性较好,同时有较好耐受性,本联合治疗有望在OAB的治疗选择上广泛推广。
Objective To explore the efficacy and adverse events of single drug or combined application of mirabelone and tolterodine sustained-release tablets in the treatment of overactive bladder(OAB).Methods From January 2019 to January 2020,150 patients with OAB diagnosed in our hospital were divided into A,B and C groups,and were divided into groups according to the ratio of 1:1:1.Mirabelone alone was used in A group at 50 mg/d.B group alone used tolterodine sustained-release tablets,4 mg/d.C group took mirabelone and tolterodine sustained-release tablets at the same time,the dose was the same as A and B groups.After 12 weeks of treatment,the efficacy was evaluated based on the change in the number of urinary incontinence and the frequency of urination at the end of 24 hours from the baseline level to the end of the treatment,and the statistical analysis of adverse events during the treatment period was conducted to assess its safety.Results A total of 143 cases(95.3%)of reliable follow-up data were obtained.The average age was 49 years(19-78 years),and 109(72.7%)OAB patients were female.Fifty(33.3%)patients experienced≥1 adverse event.There were no serious adverse events in the three treatment groups,and dry mouth was the most common adverse event(mirabelon,6%;tolterodine sustained-release tablets,12%;combined treatment group 10%).After treatment,the patients in the three groups all improved significantly(P<0.05).Compared with the monotherapy,the number of urinary incontinence and the frequency of urination were significantly improved in the combined treatment group(P<0.05).Conclusion Mirabelone combined with tolterodine sustained-release tablets is more effective and well tolerated in the treatment of OAB.This combination therapy is expected to be widely promoted in the treatment of OAB.
作者
朱蜀侠
王明松
Zhu Shuxia;Wang Mingsong(Chengdu 363 Hospital,Chengdu,Sichuan 610000,China)
出处
《四川医学》
CAS
2020年第5期510-513,共4页
Sichuan Medical Journal
关键词
膀胱过度活动症
米拉贝隆
托特罗定缓释片
尿失禁
排尿次数
overactive bladder
Mirabelone
Tolterodine Sustained-release Tablets
urinary incontinence
frequency of urination
